It is a pharma private limited company based in Nagpur, Maharashtra, India, established in 2015.
2015 | Nagpur, Maharashtra, India | Struck OffRawmax Pharmaceutical Private Limited, a struck off private limited company, was established on 19 May 2015 in Nagpur, Maharashtra, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U51101MH2015PTC264624. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
It upholds a active non-compliant status. Its leadership includes Umesh Kisanrao Wadekar (Director), Sanjay Bechan Chourasia (Director). Past directors included Shriram Manikarao Maslekar, Kamalkumar Nityanand Rawat, Amit Diware. Its latest AGM occurred on 30 September 2017, with the balance sheet filed on 31 March 2017. It is based at H No 4485/193,Kashi Nagar, Rameshwari Road,, Nagpur, Maharashtra, 440027.
U51101MH2015PTC264624
264624
19 May 2015
₹0.10 M
₹0.10 M
Roc Mumbai
Unlisted
Struck Off
Explore comprehensive insights into Rawmax Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Umesh Kisanrao Wadekar | Director | 19 May 2015 | Current |
| Sanjay Bechan Chourasia | Director | 07 Oct 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 22 Jun 2015 | Past |
| Pramod Abcsdd | Director | 01 Feb 2022 | Past |
| Pramod Abcsdd | Director | 07 Oct 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Rawmax Pharmaceutical Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 29.43% increase. The company also saw a substantial improvement in profitability, with a 87.08% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.17%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Rawmax Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Rawmax Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Rawmax Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rawmax Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Rawmax Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2017 as per latest MCA records. was recorded as a recent event.
Progress on Rawmax Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2017 with Roc Mumbai. was documented.
The activity Sanjay Bechan Chourasia was appointed as a Director was appointed as a Director on 07 Oct 2015 & has been associated with this company since 10 years 1 month . was completed.
Progress on Umesh Kisanrao Wadekar was appointed as a Director was appointed as a Director on 19 May 2015 & has been associated with this company since 10 years 6 months . was documented.
Progress on Rawmax Pharmaceutical Private Limited was registered on 19 May 2015 with Roc Mumbai & aged 10 years 6 months as per MCA records. was documented.
The CIN of Rawmax Pharmaceutical Private Limited is U51101MH2015PTC264624.
Rawmax Pharmaceutical Private Limited is headquartered at H No 4485/193,Kashi Nagar, Rameshwari Road,, Nagpur, Maharashtra, 440027.
Rawmax Pharmaceutical Private Limited was incorporated on 19 May 2015.
The current directors of Rawmax Pharmaceutical Private Limited are
The primary industry of Rawmax Pharmaceutical Private Limited is Trade.
Rawmax Pharmaceutical Private Limited is unlisted.
The authorized capital of Rawmax Pharmaceutical Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
The compliance status of Rawmax Pharmaceutical Private Limited is Active Non-Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX